Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
53.9M
-
Shares change
-
-1.9M
-
Total reported value, excl. options
-
$274M
-
Value change
-
-$13M
-
Number of buys
-
43
-
Number of sells
-
-57
-
Price
-
$5.09
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q3 2021
127 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q3 2021.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.9M shares
of 166M outstanding shares and own 32.53% of the company stock.
Largest 10 shareholders include Point72 Asset Management, L.P. (6.3M shares), VANGUARD GROUP INC (5.52M shares), BlackRock Inc. (5.05M shares), STATE STREET CORP (4.04M shares), RA CAPITAL MANAGEMENT, L.P. (3.5M shares), Candriam Luxembourg S.C.A. (3.31M shares), VICTORY CAPITAL MANAGEMENT INC (3.27M shares), ORBIMED ADVISORS LLC (1.82M shares), GREAT POINT PARTNERS LLC (1.5M shares), and RTW INVESTMENTS, LP (1.4M shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.